This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Tricida Future Growth
Future criteria checks 0/6
Key information
57.3%
Earnings growth rate
58.1%
EPS growth rate
| Pharmaceuticals earnings growth | 24.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Mar 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | -58 | -29 | -29 | 1 |
| 12/31/2022 | N/A | -109 | -89 | -89 | 1 |
| 9/30/2022 | N/A | -134 | -109 | -109 | N/A |
| 6/30/2022 | N/A | -148 | -119 | -119 | N/A |
| 3/31/2022 | N/A | -153 | -136 | -135 | N/A |
| 12/31/2021 | N/A | -177 | -140 | -140 | N/A |
| 9/30/2021 | N/A | -181 | -145 | -144 | N/A |
| 6/30/2021 | N/A | -219 | -177 | -176 | N/A |
| 3/31/2021 | N/A | -244 | -212 | -211 | N/A |
| 12/31/2020 | N/A | -265 | -233 | -231 | N/A |
| 9/30/2020 | N/A | -268 | -220 | -219 | N/A |
| 6/30/2020 | N/A | -235 | -202 | -201 | N/A |
| 3/31/2020 | N/A | -213 | -158 | -157 | N/A |
| 12/31/2019 | N/A | -177 | -131 | -130 | N/A |
| 9/30/2019 | N/A | -146 | -134 | -133 | N/A |
| 6/30/2019 | N/A | -131 | -119 | -118 | N/A |
| 3/31/2019 | N/A | -120 | -104 | -104 | N/A |
| 12/31/2018 | N/A | -103 | -96 | -95 | N/A |
| 9/30/2018 | N/A | -96 | -79 | -78 | N/A |
| 6/30/2018 | N/A | -77 | -60 | -58 | N/A |
| 3/31/2018 | N/A | -60 | -49 | -47 | N/A |
| 12/31/2017 | N/A | -41 | -41 | -40 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1T7 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1T7 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1T7 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1T7's revenue is forecast to grow faster than the German market.
High Growth Revenue: 1T7 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1T7's Return on Equity is forecast to be high in 3 years time